Lowest Price Guaranteed
Pages
306
Last Updated
July 2026
View Count
27161
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Introduction to Therapeutic Vaccines
6.2.1. Classification of Vaccines by Method of Composition
6.2.1.1. Autologous Vaccines
6.2.1.2. Allogeneic Vaccines
6.3. Classification of Vaccines by Mechanism of Action
6.3.1. Antigen Vaccines
6.3.2. Dendritic Vaccines
6.3.3. DNA Vaccines
6.3.4. Peptide Vaccines
6.4. Key Target Indications
6.4.1. Cancer
6.4.2. HIV Infection
6.4.3. HPV Infection
6.4.4. Herpes
6.5. Clinical Development and Approval of Vaccines
6.6. Concluding Remarks
7. MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Therapeutic Vaccines: Pipeline Analysis
7.2.1. Analysis by Phase of Development
7.2.2. Analysis by Type of Vaccine
7.2.3. Analysis by Type of Vaccine (by Method of Composition)
7.2.4. Analysis by Type of Therapy
7.2.5. Analysis by Therapeutic Area
7.2.6. Analysis by Route of Administration
7.2.7. Analysis by Dosage
7.3. Therapeutic Vaccines: Analysis by Vaccine Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Leading Developers
7.3.5. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. BioNTech
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Therapeutic Vaccines Portfolio
8.2.4. Recent Developments and Future Outlook
Similar details are presented for other companies mentioned below (based on information in the public domain)
8.3. Brii Biosciences
8.4. GlobeImmune
8.5. Immatics
8.6. Immune Response Biopharma
8.7. Immunitor
8.8. Inovio Pharmaceuticals
8.9. Moderna
9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Start-ups in Therapeutic Vaccines Market
9.2.1. Analysis by Location of Headquarters
9.3. Benchmarking of Start-ups
9.3.1. Analysis by Supplier Strength
9.3.2. Analysis by Pipeline Strength
9.3.3. Analysis by Pipeline Maturity
9.3.4. Analysis by Financial Investment
9.3.5. Analysis by Partnership Activity
9.3.6. Start-ups Health Indexing: Roots Analysis Perspective
10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Therapeutic Vaccines: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Trial Recruitment Status
10.3.5. Analysis by Study Design
10.3.6. Analysis by Trial Focus Area
10.3.7. Analysis by Therapeutic Area
10.3.8. Analysis by Type of Sponsor / Collaborator
10.3.9. Most Active Players: Analysis by Number of Registered Trials
10.3.10. Geographical Analysis by Number of Registered Trials
10.3.11. Geographical Analysis by Enrolled Patient Population
11. ACADEMIC GRANTS ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Therapeutic Vaccines: Academic Grant Analysis
11.3.1. Analysis by Year of Grant Award
11.3.2. Analysis by Amount Awarded
11.3.3. Analysis by Administering Institute Center
11.3.4. Analysis by Support Period
11.3.5. Analysis by Administering Institute Center and Support Period
11.3.6. Analysis by Type of Grant Application
11.3.7. Analysis by Purpose of Grant Award
11.3.8. Analysis by Activity Code
11.3.9. Analysis by Study Section Involved
11.3.10. Analysis by Type of Recipient Organization
11.3.11. Word Cloud Analysis: Emerging Focus Areas
11.3.12. Geographical Distribution of Recipient Organizations
11.3.13. Popular NIH Departments: Analysis by Number of Grants
11.3.14. Prominent Program Officers: Analysis by Number of Grants
11.3.15. Popular Recipient Organizations: Analysis by Number of Grants
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Therapeutic Vaccines: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year of Partnership and Type of Partner
12.3.4. Analysis by Type of Partnership and Type of Partner
12.3.5. Analysis by Focus Area
12.3.6. Analysis by Therapeutic Area
12.3.7. Most Active Players: Analysis by Number of Partnerships
12.3.8. Regional Analysis
12.3.8.1. Intercontinental and Intracontinental Agreements
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Therapeutic Vaccines Market, till 2035
13.4. Global Therapeutic Vaccines Market, till 2035: Distribution by Type of Vaccine
13.5. Global Therapeutic Vaccines Market, till 2035: Distribution by Method of Vaccine Composition
13.6. Global Therapeutic Vaccines Market, till 2035: Distribution by Type of Therapy
13.7. Global Therapeutic Vaccines Market, till 2035: Distribution by Therapeutic Area
13.8. Global Therapeutic Vaccines Market, till 2035: Distribution by Route of Administration
13.9. Global Therapeutic Vaccines Market, till 2035: Geographical Distribution
13.9.1. Therapeutic Vaccines Market in US, till 2035
13.9.2. Therapeutic Vaccines Market in Canada, till 2035
13.9.3. Therapeutic Vaccines Market in UK, till 2035
13.9.4. Therapeutic Vaccines Market in Germany, till 2035
13.9.5. Therapeutic Vaccines Market in France, till 2035
13.9.6. Therapeutic Vaccines Market in Italy, till 2035
13.9.7. Therapeutic Vaccines Market in Spain, till 2035
13.9.8. Therapeutic Vaccines Market in Australia, till 2035
13.9.9. Therapeutic Vaccines Market in Japan, till 2035
13.9.10. Therapeutic Vaccines Market in Korea, till 2035
13.9.11. Therapeutic Vaccines Market in Brazil, till 2035
13.9.12. Therapeutic Vaccines Market in Israel, till 2035
13.10. Global Therapeutic Vaccines Market, till 2035: Sales Forecast
14. CASE STUDY: GLOBAL PREVENTIVE VACCINES
14.1. Chapter Overview
14.2. Preventive Vaccines: Overall Market Landscape
14.2.1. Marketed Vaccines Landscape
14.2.2. Clinical-Stage Vaccines Landscape
14.2.3. Analysis by Phase of Development
14.2.4. Analysis by Route of Administration
14.2.5. Analysis by Type of Vaccine API
14.2.6. Analysis by Dosage Form
14.2.7. Analysis by Therapeutic Area
14.2.8. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
14.2.9. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development
15. CASE STUDY: VACCINE CONTRACT MANUFACTURING MARKET
15.1. Chapter Overview
15.2. Vaccine Contract Manufacturers: Overall Market Landscape
15.2.1. Analysis by Year of Establishment
15.2.2. Analysis by Company Size and Geographical Location
15.2.3. Analysis by Geography
15.2.4. Analysis by Type of Service(s) Offered
15.2.5. Analysis by Scale of Operation
15.2.6. Analysis by Type of Expression System(s) Used
15.2.7. Analysis by Type of Vaccines Manufactured
16. CONCLUDING REMARKS
17. EXECUTIVE INSIGHTS
17.1. Company A
17.1.1. Company Overview
17.1.2. Interview Transcript: Chief Executive Officer and Chief Scientific Officer
17.2. Company B
17.2.1. Company Overview
17.2.2. Interview Transcript: Science Director Advanced Modalities, Senior Research Leader, and Director of Scientific Advisory Services
17.3. Company C
17.3.1. Company Overview
17.3.2. Interview Transcript: Director of Head and Neck Cancer Research
17.4. Company D
17.4.1. Company Overview
17.4.2. Interview Transcript: Associate Professor of Surgery, Integrative Immunology, and Pathology
17.5. Company E
17.5.1. Company Overview
17.5.2. Interview Transcript: Physician Scientists
17.6. Company F
17.6.1. Company Overview
17.6.2. Interview Transcript: Pediatric Oncologist
17.7. Company G
17.7.1. Company Overview
17.7.2. Interview Transcript: Associate Director for Translational Research
17.8. Company H
17.8.1. Company Overview
17.8.2. Interview Transcript: Research Group Leader
17.9. Company I
17.9.1. Company Overview
17.9.2. Interview Transcript: Senior Public Health Researcher
17.10. Company J
17.10.1. Company Overview
17.10.2. Interview Transcript: Radiology Resident
18. APPENDIX I: TABULATED DATA
19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 6.1 Difference between Preventive Vaccines and Therapeutic Vaccines
Figure 6.2 Different Routes of Vaccine Administration
Figure 7.1 Therapeutic Vaccines: Distribution by Phase of Development
Figure 7.2 Therapeutic Vaccines: Distribution by Type of Vaccine
Figure 7.3 Therapeutic Vaccines: Distribution by Type of Vaccine (by Method of Composition)
Figure 7.4 Therapeutic Vaccines: Distribution by Type of Therapy
Figure 7.5 Therapeutic Vaccines: Distribution by Therapeutic Area
Figure 7.6 Therapeutic Vaccines: Distribution by Route of Administration
Figure 7.7 Therapeutic Vaccines: Distribution by Dosage
Figure 7.8 Therapeutic Vaccines Developers: Distribution by Type of Developers
Figure 7.9 Therapeutic Vaccines Developers: Distribution by Year of Establishment
Figure 7.10 Therapeutic Vaccines Developers: Distribution by Company Size
Figure 7.11 Therapeutic Vaccines Developers: Distribution by Location of Headquarters
Figure 7.12 Leading Developers
Figure 7.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
Figure 8.1 BioNTech: Annual Revenues, Since 2021 (USD Million)
Figure 8.2 Brii Biosciences: Annual Revenues, Since 2021 (USD Million)
Figure 8.3 GlobeImmune: Annual Revenues, Since 2021 (USD Million)
Figure 8.4 Immatics: Annual Revenues, Since 2021 (USD Million)
Figure 8.5 Immune Response Biopharma: Annual Revenues, Since 2021 (USD Million)
Figure 8.6 Inovio Pharmaceuticals: Annual Revenues, Since 2021 (USD Million)
Figure 8.7 Moderna: Annual Revenues, Since 2021 (USD Million)
Figure 9.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 9.2 Startup-Health Indexing: Distribution by Supplier Strength
Figure 9.3 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 9.4 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 9.5 Startup-Health Indexing: Distribution by Financial Investment
Figure 9.6 Startup-Health Indexing: Distribution by Partnership Activity
Figure 9.7 Startup-Health Indexing: Roots Analysis Perspective
Figure 9.8 Spider Web Analysis: Leading Companies
Figure 10.1 Clinical Trial Analysis: Scope and Methodology
Figure 10.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2021
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2021
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 10.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 10.7 Clinical Trial Analysis: Distribution by Study Design
Figure 10.8 Clinical Trial Analysis: Distribution by Trial Focus Area
Figure 10.9 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.11 Most Active Players: Distribution by Number of Registered Trials
Figure 10.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 10.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 11.1 Grant Analysis: Cumulative Year-wise Trend, Since 2021
Figure 11.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million) Since 2021
Figure 11.3 Grant Analysis: Distribution by Administering Institute Center
Figure 11.4 Grant Analysis: Distribution by Support Period
Figure 11.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 11.6 Grant Analysis: Distribution by Type of Grant Application
Figure 11.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 11.8 Grant Analysis: Distribution by Activity Code
Figure 11.9 Grant Analysis: Distribution by Study Section Involved
Figure 11.10 Grant Analysis: Distribution by Type of Recipient Organization
Figure 11.11 Word Cloud Analysis: Emerging Focus Areas
Figure 11.12 Grant Analysis: Geographical Distribution of Recipient Organizations
Figure 11.13 Popular NIH Departments: Distribution by Number of Grants
Figure 11.14 Prominent Program Officers: Distribution by Number of Grants
Figure 11.15 Popular Recipient Organizations: Distribution by Number of Grants
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 12.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 12.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 12.6 Partnerships and Collaborations: Distribution by Focus Areas
Figure 12.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 12.8 Most Active Players: Distribution by Number of Partnerships
Figure 12.9 Partnerships and Collaborations: Regional Distribution
Figure 12.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 13.1 Global Therapeutic Vaccines Market, till 2035 (USD Million)
Figure 13.2 Global Therapeutic Vaccines Market: Distribution by Type of Vaccine, till 2035
Figure 13.3 Global Therapeutic Vaccines Market: Distribution by Method of Vaccine Composition, till 2035
Figure 13.4 Global Therapeutic Vaccines Market: Distribution by Type of Therapy, till 2035
Figure 13.5 Global Therapeutic Vaccines Market: Distribution by Therapeutic Area, till 2035
Figure 13.6 Global Therapeutic Vaccines Market: Distribution by Route of Administration, till 2035
Figure 13.7 Therapeutic Vaccines Market in US, till 2035
Figure 13.8 Therapeutic Vaccines Market in Canada, till 2035
Figure 13.9 Therapeutic Vaccines Market in UK, till 2035
Figure 13.10 Therapeutic Vaccines Market in Germany, till 2035
Figure 13.11 Therapeutic Vaccines Market in France, till 2035
Figure 13.12 Therapeutic Vaccines Market in Italy, till 2035
Figure 13.13 Therapeutic Vaccines Market in Spain, till 2035
Figure 13.14 Therapeutic Vaccines Market in Australia, till 2035
Figure 13.15 Therapeutic Vaccines Market in Japan, till 2035
Figure 13.16 Therapeutic Vaccines Market in Korea, till 2035
Figure 13.17 Therapeutic Vaccines Market in Brazil, till 2035
Figure 13.18 Therapeutic Vaccines Market in Israel, till 2035
Figure 14.1 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Figure 14.2 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Figure 14.3 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Figure 14.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Figure 14.5 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Figure 14.6 Clinical-Stage Preventive Vaccines: Distribution by Therapeutic Area
Figure 14.7 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 14.8 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 15.1 Vaccine CMOs: Distribution by Year of Establishment
Figure 15.2 Vaccine CMOs: Distribution by Company Size and Geographical Location
Figure 15.3 World Map Representation: Distribution by Geography
Figure 15.4 Vaccine CMOs: Distribution by Types of Service(s) Offered
Figure 15.5 Vaccine CMOs: Distribution by Additional Services Offered and Location of Headquarters
Figure 15.6 Vaccine CMOs: Distribution by Scale of Operation
Figure 15.7 Vaccine CMOs: Distribution by Type of Expression System(s) Used
Figure 15.8 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
Figure 16.1 Concluding Remarks: Overall Market Landscape
Figure 16.2 Concluding Remarks: Clinical Trial Analysis
Figure 16.3 Concluding Remarks: Academic Grant Analysis
Figure 16.4 Concluding Remarks: Partnerships and Collaborations
Figure 16.5 Concluding Remarks: Start-up Health Indexing
Figure 16.6 Concluding Remarks: Market Forecast and Opportunity Analysis
Table 6.1 Vaccines for Cancer Treatment
Table 6.2 Vaccines for HIV Treatment
Table 6.3 Vaccines for HPV Treatment
Table 6.4 Vaccines for Herpes Treatment
Table 7.1 List of Therapeutic Vaccines
Table 8.1 Global Therapeutic Vaccines: List of Companies Profiled
Table 8.2 BioNTech: Company Snapshot
Table 8.3 Vaccine Profile: BNT-111
Table 8.4 Vaccine Profile: BNT-112
Table 8.5 Vaccine Profile: BNT-113
Table 8.6 Vaccine Profile: BNT-115
Table 8.7 Vaccine Profile: BNT-116
Table 8.8 Vaccine Profile: BNT-122
Table 8.9 Vaccine Profile: W_pro1
Table 8.10 Vaccine Profile: HPV Vaccine
Table 8.11 Vaccine Profile: IVAC MUTANOME
Table 8.12 Vaccine Profile: RBL001/RBL002
Table 8.13 Vaccine Profile: NEO-PV-01
Table 8.14 BioNTech: Recent Developments and Future Outlook
Table 8.15 Brii Biosciences: Company Snapshot
Table 8.16 Vaccine Profile: Bri-179
Table 8.17 Vaccine Profile: Bri-835
Table 8.18 Vaccine Profile: Bri-778
Table 8.19 Vaccine Profile: Bri-732
Table 8.20 Vaccine Profile: Bri-296
Table 8.21 Brii Biosciences: Recent Developments and Future Outlook
Table 8.22 GlobeImmune: Company Snapshot
Table 8.23 Vaccine Profile: GI-6301
Table 8.24 Vaccine Profile: GI-6207
Table 8.25 Vaccine Profile: GI-4000
Table 8.26 Vaccine Profile: GS-4774
Table 8.27 Vaccine Profile: GI-5005
Table 8.28 GlobeImmune: Recent Developments and Future Outlook
Table 8.29 Immatics: Company Snapshot
Table 8.30 Vaccine Profile: APVAC
Table 8.31 Vaccine Profile: IMA901
Table 8.32 Vaccine Profile: IMA910
Table 8.33 Vaccine Profile: IMA950
Table 8.34 Vaccine Profile: IMA970A
Table 8.35 Immatics: Recent Developments and Future Outlook
Table 8.36 Immune Response Biopharma: Company Snapshot
Table 8.37 Vaccine Profile: IR103
Table 8.38 Vaccine Profile: REMUNE
Table 8.39 Vaccine Profile: NeuroVax
Table 8.40 Vaccine Profile: RAVAX
Table 8.41 Vaccine Profile: Zorcell
Table 8.42 Immune Response Biopharma: Recent Developments and Future Outlook
Table 8.43 Immunitor: Company Snapshot
Table 8.44 Vaccine Profile: Atherosclerosis Vaccine
Table 8.45 Vaccine Profile: V3-MOMMO
Table 8.46 Vaccine Profile: Hepcortespenlisimut-L
Table 8.47 Vaccine Profile: V-Boost
Table 8.48 Vaccine Profile: V3-OVA
Table 8.49 Vaccine Profile: V3-Myoma
Table 8.50 Vaccine Profile: V3-Cervix
Table 8.51 Vaccine Profile: V7
Table 8.52 Vaccine Profile: V3-X
Table 8.53 Vaccine Profile: V3-P
Table 8.54 Vaccine Profile: V-Endo
Table 8.55 Vaccine Profile: V8
Table 8.56 Vaccine Profile: V-SARS
Table 8.57 Immunitor: Recent Developments and Future Outlook
Table 8.58 Innovio Pharmaceuticals: Company Snapshot
Table 8.59 Vaccine Profile: VGX-3100
Table 8.60 Vaccine Profile: INO-3107
Table 8.61 Vaccine Profile: INO-5401
Table 8.62 Vaccine Profile: INO-5151
Table 8.63 Vaccine Profile: INO-3112
Table 8.64 Vaccine Profile: INO-5150
Table 8.65 Vaccine Profile: INO-3106
Table 8.66 Vaccine Profile: INO-1800
Table 8.67 Innovio Pharmaceuticals: Recent Developments and Future Outlook
Table 8.68 Moderna: Company Snapshot
Table 8.69 Vaccine Profile: mRNA-4157
Table 8.70 Vaccine Profile: mRNA-3927
Table 8.71 Vaccine Profile: mRNA-3705
Table 8.72 Vaccine Profile: mRNA-3745
Table 8.73 Vaccine Profile: mRNA-5671
Table 8.74 Vaccine Profile: mRNA-2752
Table 8.75 Moderna: Recent Developments and Future Outlook
Table 12.1 Global Therapeutic Vaccines: List of Partnerships and Collaborations, Since 2021
Table 14.1 Therapeutic Vaccines: Distribution by Phase of Development
Table 14.2 Therapeutic Vaccines: Distribution by Type of Vaccine
Table 14.3 Therapeutic Vaccines: Distribution by Type of Vaccine (by Method of Composition)
Table 14.4 Therapeutic Vaccines: Distribution by Type of Therapy
Table 14.5 Therapeutic Vaccines: Distribution by Therapeutic Area
Table 14.6 Therapeutic Vaccines: Distribution by Route of Administration
Table 14.7 Therapeutic Vaccines: Distribution by Dosage
Table 14.8 Therapeutic Vaccines Developers: Distribution by Type of Developers
Table 14.9 Therapeutic Vaccines Developers: Distribution by Year of Establishment
Table 14.10 Therapeutic Vaccines Developers: Distribution by Company Size
Table 14.11 Therapeutic Vaccines Developers: Distribution by Location of Headquarters
Table 14.12 Leading Developers
Table 14.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
Table 14.14 BioNTech: Annual Revenues, Since 2021 (USD Million)
Table 14.15 Brii Biosciences: Annual Revenues, Since 2021 (USD Million)
Table 14.16 GlobeImmune: Annual Revenues, Since 2021 (USD Million)
Table 14.17 Immatics: Annual Revenues, Since 2021 (USD Million)
Table 14.18 Immune Response Biopharma: Annual Revenues, Since 2021 (USD Million)
Table 14.19 Inovio Pharmaceuticals: Annual Revenues, Since 2021 (USD Million)
Table 14.20 Moderna: Annual Revenues, Since 2021 (USD Million)
Table 14.21 Clinical Trial Analysis: Scope and Methodology
Table 14.22 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Table 14.23 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2022
Table 14.24 Clinical Trial Analysis: Distribution by Trial Phase
Table 14.25 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.26 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 14.27 Clinical Trial Analysis: Distribution by Study Design
Table 14.28 Clinical Trial Analysis: Distribution by Trial Focus Area
Table 14.29 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 14.30 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.31 Most Active Players: Distribution by Number of Registered Trials
Table 14.32 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 14.33 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 14.34 Grant Analysis: Cumulative Year-wise Trend, 2016-2022
Table 14.35 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million) 2016-2022
Table 14.36 Grant Analysis: Distribution by Administering Institute Center
Table 14.37 Grant Analysis: Distribution by Support Period
Table 14.38 Grant Analysis: Distribution by Administering Institute Center and Support Period
Table 14.39 Grant Analysis: Distribution by Type of Grant Application
Table 14.40 Grant Analysis: Distribution by Purpose of Grant Award
Table 14.41 Grant Analysis: Distribution by Activity Code
Table 14.42 Grant Analysis: Distribution by Study Section Involved
Table 14.43 Grant Analysis: Distribution by Type of Recipient Organization
Table 14.44 Grant Analysis: Geographical Distribution of Recipient Organizations
Table 14.45 Popular NIH Departments: Distribution by Number of Grants
Table 14.46 Prominent Program Officers: Distribution by Number of Grants
Table 14.47 Popular Recipient Organizations: Distribution by Number of Grants
Table 14.48 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2021
Table 14.49 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.50 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Table 14.51 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.52 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.53 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 14.54 Most Active Players: Distribution by Number of Partnerships
Table 14.55 Partnerships and Collaborations: Regional Distribution
Table 14.56 Startup-Health Indexing: Distribution by Location of Headquarters
Table 14.57 Startup-Health Indexing: Distribution by Supplier Strength
Table 14.58 Startup-Health Indexing: Distribution by Pipeline Strength
Table 14.59 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 14.60 Startup-Health Indexing: Distribution by Financial Investment
Table 14.61 Startup-Health Indexing: Distribution by Partnership Activity
Table 14.62 Startup-Health Indexing: Roots Analysis Perspective
Table 14.63 Global Therapeutic Vaccines Market, 2022-2035 (USD Million)
Table 14.64 Global Therapeutic Vaccines Market: Distribution by Type of Vaccine, till 2035
Table 14.65 Global Therapeutic Vaccines Market: Distribution by Method of Vaccine Composition, till 2035
Table 14.66 Global Therapeutic Vaccines Market: Distribution by Type of Therapy, till 2035
Table 14.67 Global Therapeutic Vaccines Market: Distribution by Therapeutic Area, till 2035
Table 14.68 Global Therapeutic Vaccines Market: Distribution by Route of Administration, till 2035
Table 14.69 Therapeutic Vaccines Market in US, till 2035
Table 14.70 Therapeutic Vaccines Market in Canada, till 2035
Table 14.71 Therapeutic Vaccines Market in UK, till 2035
Table 14.72 Therapeutic Vaccines Market in Germany, till 2035
Table 14.73 Therapeutic Vaccines Market in France, till 2035
Table 14.74 Therapeutic Vaccines Market in Italy, till 2035
Table 14.75 Therapeutic Vaccines Market in Spain, till 2035
Table 14.76 Therapeutic Vaccines Market in Australia, till 2035
Table 14.77 Therapeutic Vaccines Market in Japan, till 2035
Table 14.78 Therapeutic Vaccines Market in Korea, till 2035
Table 14.79 Therapeutic Vaccines Market in Brazil, till 2035
Table 14.80 Therapeutic Vaccines Market in Israel, till 2035